Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

Candel Therapeutics, Inc. CADL announced that the FDA has granted Fast Track designation to its investigational adenovirus candidate CAN-2409 plus prodrug (valacyclovir) for the treatment of pancreatic ductal adenocarcinoma (PDAC). Shares of the company were up 20.6% on Dec 12 following the announcement of the news.